Atara Biotherapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Atara Biotherapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 90% in 3 years; of every extra $100 of sales, $456 became extra profit. Higher than 92% of Healthcare companies in United States.
- Cash Locked Ratio: For every $100 of sales, $1 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $55 tied up three years earlier. Less money tied up than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$1For every $100 of sales, $1 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $55 tied up three years earlier.
Less money tied up than 89% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$456Sales grew 90% in 3 years; of every extra $100 of sales, $456 became extra profit.
Higher than 92% of Healthcare companies in United States.
Asset Productivity Ratio
+90% / -95%In 3 years sales changed by +90% while total assets changed by -95%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-49.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 70% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Atara Biotherapeutics, Inc. made a loss over the last year. Atara Biotherapeutics, Inc. owes $2.76 for every $1 it owns. Atara Biotherapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAtara Biotherapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-2.56Atara Biotherapeutics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$95 MThe total market value of all of Atara Biotherapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeAtara Biotherapeutics, Inc.'s net worth is negative ($37 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
2.76×Atara Biotherapeutics, Inc. owes $2.76 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Dividend yield
NoneAtara Biotherapeutics, Inc. does not currently pay a dividend.
Revenue growth
-6%Revenue fell 6% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Profit growth
Back to profitAtara Biotherapeutics, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
27.1%Atara Biotherapeutics, Inc. keeps $27 of every $100 of revenue as net profit.
Cash quality
-1.6×Cash from Atara Biotherapeutics, Inc.'s business was -1.6× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
9.5×Atara Biotherapeutics, Inc.'s operating profit covered its interest costs 9.5 times in the year to Dec 2025.
Cash vs debt
Net debtAtara Biotherapeutics, Inc. had $2 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Atara Biotherapeutics, Inc. owe compared with what it owns?
Atara Biotherapeutics, Inc. owes $2.76 for every $1 it owns, so it owes more than it owns, higher than 98% of Healthcare companies in United States.
Does Atara Biotherapeutics, Inc. pay a dividend?
No. Atara Biotherapeutics, Inc. does not currently pay a dividend.
Is Atara Biotherapeutics, Inc.'s revenue growing?
Revenue fell 6% in the year to Dec 2025, and grew 24% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.